Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

NCT00383851 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: ATN-224
DRUG: Temozolomide

Sponsor

Attenuon